← Back to feed

Avacta Group

AVCT · AIM · Health Care · mcap £329m today

All announcements

All RNS · 55 Key events · 48

06 Oct 26

Capital Access Window - Avacta Group Plc

RNS 9808457 ↗
06 Oct 26

Results of Placing and Subscription

The Placing Shares and the Subscription Shares in aggregate represent approximately 3.9 per cent of the existing issued ordinary share capital of the Company and the Issue Price represents a discount of approximately 5.6 per cent to the closing mid-market...
RNS 9807660 ↗
05 Oct 26

Proposed Fundraise to raise approximately £12.5m

Proposed Placing via an Accelerated Bookbuild and Subscription to Raise Approximately £12.5 Million
RNS 9807440 ↗
30 Sep 26

Capital Access Window - Avacta Group Plc

RNS 9798420 ↗
30 Sep 26

Capital Access Window

LONDON and PHILADELPHIA - September 30, 2026 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, announces its intention to utilise AIM's new Capital Access Window rule in connection with a proposed...
RNS 9797862 ↗
30 Sep 26

Half-year Results

Interim Results for the Six Months to June 30, 2026, and Business Update
RNS 9797667 ↗
25 Sep 26

Pre|CISION® Platform Wins R&D Achievement Award

"Our recent clinical data with AVA6103 point to the proof of this mechanism and we look forward to continued updates on the program and our full pipeline.
RNS 9791095 ↗
25 Sep 26

Further Demonstration of Potential of AVA6103

The FOCUS-01 Clinical Trial Design and Preclinical Data Further Demonstrate the Potential of AVA6103 at AACR Conference on Pancreatic Cancer
RNS 9790276 ↗
16 Sep 26

Clinical Proof of Mechanism for preCISION Platform

Preliminary data from the Phase 1a trial of AVA6103 in patients with select solid tumors demonstrate proof of mechanism with two key findings:
RNS 9773933 ↗
14 Sep 26

Mats Blom to Board as Chair of Audit Committee

Avacta Appoints Mats Blom to the Board of Directors as Chair of Audit Committee
RNS 9769116 ↗
04 Sep 26

Accelerated Payment Convertible Bond Installment

LONDON and PHILADELPHIA - September 4, 2026 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, announces that it has received an accelerated payment notice from the convertible bond holder in respect...
RNS 9755174 ↗
01 Sep 26

Share Option Awards to Management Team at Avacta

Share Option Awards to Management Team at Avacta
RNS 9747219 ↗
09 Jul 26

Accelerated Amortized Payment of Bond Installment

LONDON and PHILADELPHIA - July 9, 2026 - Avacta (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, confirms that it has received an accelerated payment notice from the convertible bond holder in respect of the January 2026...
RNS 9659734 ↗
08 Jul 26

Avacta Appoints Patrick Vink Deputy Chairman

Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman
RNS 9657198 ↗
25 Jun 26

Platform-Validating Data with Faridoxorubicin

Avacta Reports Platform-Validating Data with Faridoxorubicin during BIO International Conference
RNS 9635409 ↗
25 Jun 26

FDA Agreement on Pivotal Trial Design for AVA6000

FDA Agreement on Pivotal Trial Design for AVA6000 in Patients with Salivary Gland Cancer
RNS 9635408 ↗
23 Jun 26

Result of AGM
RNS 9630710 ↗
22 Jun 26

Year-to-date business update ahead of AGM

Year-to-date business update ahead of Annual General Meeting
RNS 9628655 ↗
05 Jun 26

Oversubscribed Strategic Equity Fundraise of £9m

Funds to be used for Convertible Bond repayments
RNS 9603068 ↗
01 Jun 26

Block Listing - Application to AIM
RNS 9595532 ↗
01 Jun 26

Clinical data on AVA6000 in salivary gland cancers

Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026
RNS 9593270 ↗
29 May 26

Posting of Annual Report and Notice of AGM
RNS 9590924 ↗
29 May 26

Board Director Changes

Shaun Chilton, who was appointed to the Board in 2022 and has served as non-executive Chairman since 2024, has decided not to seek re-election at the AGM.
RNS 9590897 ↗
19 May 26

Unaudited Preliminary Full Year 2025 Results

Unaudited Preliminary Results for the Year Ended December 31, 2025
RNS 9574278 ↗
13 May 26

Notice of Preliminary Results and Presentation

Christina Coughlin, Chief Executive Officer, and Brian Hahn, Chief Financial Officer, will deliver a live presentation via Investor Meet Company at 14:00 BST on May 19, 2026.
RNS 9565157 ↗
13 May 26

Issue of Equity and Total Voting Rights
RNS 9565096 ↗
06 May 26

Pre|CISION® payload release vs approved ADCs

"We continue to build momentum and enhance our IP - at a pace that we are confident exceeds industry norms."
RNS 9553607 ↗
28 Apr 26

Block Listing Six Monthly Return
RNS 9540634 ↗
21 Apr 26

Avacta data AACR underline AVA6103 profile

Presentation of additional analyses from FAP-Exd (AVA6103) study shows robust activity in PDX models with low FAP expression and more favorable kinetic profile compared to the marketed antibody-drug conjugate (ADC) Enhertu®
RNS 9529286 ↗
14 Apr 26

Christina Coughlin - In Vivo 2026 Rising Leader

Avacta CEO Christina Coughlin Named as One of In Vivo's 2026 Rising Leaders
RNS 9519479 ↗
09 Apr 26

Q1 2026 Business Update

· Completed a successful financing with an oversubscribed placing and subscription raising £10 million, as announced on 27 March 2026, extending the cash runway into early Q1 2027 and allowing the Company to retain 100% ownership of all assets in the pipeline.
RNS 9511297 ↗
08 Apr 26

Science Day 2026

The Avacta Science Day event for investors will take place in Central London on May 6, 2026 commencing at 10.30 AM, at the Royal Society of Chemistry, Burlington House, Piccadilly, London W1J 0BA.
RNS 9509210 ↗
31 Mar 26

First patient treated in Phase 1 trial of AVA6103

Enrollment underway in second Avacta clinical program at first three specialist U.S. oncology centers
RNS 9499205 ↗
27 Mar 26

Result of Oversubscribed Fundraise

Together, the Placing Shares and the Subscription Shares in aggregate represent approximately 3.60 per cent. of the existing issued ordinary share capital of the Company and the Issue Price represents a discount of approximately 9.35 per cent. to the...
RNS 9494789 ↗
26 Mar 26

Proposed Fundraise to raise approximately £10m

ALL DETAILS IN THIS ANNOUNCEMENT UNCHAGED OTHER THAN THE HEADING CHANGED TO "PROPOSE FUNDRAISE TO RAISE APPROXIMATELY £10m"
RNS 9494596 ↗
26 Mar 26

Issue of Equity
RNS 9494531 ↗
17 Mar 26

Presentations of pre|CISION® Platform Candidates

Authors: Curtis Rink, Tom Clough, Ellen Watts, Folake Orafidiya, Marine Houée, Sophie Brown, Victoria Juskaite, Gezim Lahu, Ruairidh Edwards, Karen Campbell, Dave Liebowitz, David Jones, Michelle Morrow, Francis Wilson
RNS 9477029 ↗
16 Mar 26

Phase 1 study opening for AVA6103

Specialty U.S. oncology centers open for recruitment in Virginia and Texas
RNS 9474628 ↗
24 Feb 26

PreCISION payload delivery advantage over ADC

Experimental data from FAP-Exd (AVA6103) demonstrates a more favorable profile compared to the marketed Antibody Drug Conjugate (ADC) Enhertu®
RNS 9443365 ↗
18 Feb 26

Avacta to Participate in Conference March 2026

Avacta to Participate in Investor Conference in March 2026
RNS 9435246 ↗
09 Feb 26

Appointment of CSO

Avacta appoints Francis Wilson as Chief Scientific Officer
RNS 9419976 ↗
03 Feb 26

Faridoxorubicin Program Clinical Updates

Avacta announces two key clinical updates to its faridoxorubicin program
RNS 9403571 ↗
21 Jan 26

FDA Clearance of IND Application for AVA6103

The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026
RNS 9370866 ↗
20 Jan 26

Year-end trading update

o In December 2025 Avacta reported highly encouraging efficacy and safety data from the cohort of patients enrolled with salivary gland cancer where a disease control rate of 90% is maintained in the full cohort (link)
RNS 9367834 ↗
20 Jan 26

Appointment of Nominated Adviser & TVR

The Company's issued ordinary share capital is 440,415,495 Ordinary Shares.
RNS 9367763 ↗
18 Dec 25

Avacta reports new AVA6103 pharmacology data

Avacta reports new pharmacology data for FAP-Exd (AVA6103)
RNS 9305039 ↗
17 Dec 25

Faridoxorubicin Phase 1b SGC data

Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers
RNS 9301741 ↗
08 Dec 25

Preliminary Data in Faridoxorubicin Phase 1b Trial

Avacta Announces the Preliminary Clinical Data in the Faridoxorubicin Phase 1b Trial in the Salivary Gland Cancer Cohort
RNS 9281206 ↗
03 Nov 25

Completion of Placing and TVR

The Company's enlarged issued ordinary share capital is 436,445,681 Ordinary Shares.
RNS 9208439 ↗
27 Oct 25

Block Listing Six Monthly Return
RNS 9197274 ↗
27 Oct 25

Avacta presents preclinical data at AACR-NCI-EORTC

First-in-class dual payload peptide drug conjugate delivers two complementary therapies from a single molecule with potential to overcome resistance and maximize tumor control
RNS 9195065 ↗
23 Oct 25

Notice of Investor Presentation

Christina Coughlin, Chief Executive Officer, David Liebowitz, Chief Medical Officer, Francis Wilson, VP Chemistry and Ruairidh Edwards, Translational Scientist will deliver a presentation via Investor Meet Company at 16:00 BST on Wednesday October 29, 2025.
RNS 9190790 ↗
20 Oct 25

Equity fundraise of £16 million

The net proceeds of the Placing provide additional working capital to progress the Company's R&D programs into 2H 2026 including progressing the faridoxorubicin Phase 1b trial and planned initiation of the FAP-EXd Phase Ia trial.
RNS 9180541 ↗
20 Oct 25

Avacta Presents Phase 1a Data for Faridoxorubicin

Median progression free survival (PFS) has not been reached in the cohort of patients with salivary gland cancer with PFS follow up suggesting a more than doubling of the benchmark PFS and a disease control rate of 91%
RNS 9180382 ↗
13 Oct 25

Avacta to present data at EORTC-NCI-AACR

Groundbreaking oncology development with the first dual payload peptide drug conjugate platform, establishing Avacta as a leader in combination therapy innovation
RNS 9166006 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.